Harry J. Buncke to M. Gazi Yaşargil: a historical lesson in cross-specialty microsurgical innovation
Listen to this summary
This historical review seeks to illustrate the impact of Dr. Harry J. Buncke's innovations in microsurgery on the field of neurosurgery, particularly through his collaboration with Dr. M. Gazi Yaşargil. The authors highlight how Buncke's advancements in microsurgical techniques and instrumentation laid the groundwork for neurosurgical procedures, specifically the first superficial temporal artery-to-middle cerebral artery bypass. By examining the exchange of knowledge at the 1966 Vermont Microvascular Surgery Conference, the paper emphasizes the importance of cross-specialty collaboration in advancing surgical practices.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Journal of neurosurgery
View all →Jun 5, 2026 · Journal of neurosurgery
Anatomy of the bony canal containing the middle meningeal artery for a vessel-sparing craniotomy in moyamoya disease
Jun 5, 2026 · Journal of neurosurgery
Enhanced Recovery After Surgery in clipping surgery for unruptured cerebral aneurysm: prospective nonrandomized controlled trial
More in Neurological Surgery
View all →Nov 19, 2026 · Lancet (London, England)
Spontaneous coronary artery dissection: implications for women's health, clinical care, and future research.
Nov 19, 2026 · Lancet (London, England)
Reproductive health in women in Britain from 2010 to 2024: findings from repeated, cross-sectional National Surveys of Sexual Attitudes and Lifestyles (Natsal).
Nov 19, 2026 · Lancet (London, England)
Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.
Nov 19, 2026 · The New England journal of medicine
Assessing Multiple Treatment Regimens for Tuberculosis.
Nov 18, 2026 · The New England journal of medicine
Acute Respiratory Distress Syndrome.
Nov 17, 2026 · Lancet (London, England)
Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial.
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


